Investor Says Biotech Co. Hid Blood Treatment Funding Woes

By Ryan Harroff · January 5, 2023, 5:46 PM EST

Israeli biotechnology company BioLine misled the public and its shareholders about its financing shortfalls for a new blood therapy, then ultimately caused a 33% stock drop when it made moves to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

IN RE BIOLINERX LTD. SECURITIES LITIGATION

Case Number

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

January 05, 2023

Recent Articles By Ryan

November 14, 2024
Boehringer Says Inhaler Antitrust Suit 'Fails On Its Face'
November 13, 2024
Premier Health Client Wants Out Of Ex-Director's Age Bias Suit
November 01, 2024
Columbus Doctor Found Guilty In $1.5M Medicaid Scam
October 18, 2024
NC Hospital Fights Competitor's Expansion Bid Approval
October 11, 2024
Nursing Home Operator Hit With OT Suit In Ohio
October 09, 2024
Ohio Worker Says Health Co. Doesn't Pay OT Or Promised Wages
October 09, 2024
Novant Ex-Exec's Counsel Wins $154K In Fees For Race Case
October 08, 2024
NC Judge Scolds Clinic And Hospital Over Bids To Seal TM Case
September 30, 2024
Macy's Can't Dodge DOL's Tobacco Surcharge Program Suit
September 24, 2024
Buyers Seek $97M Fees From $335M Drug Price-Fixing Deals